维生素D治疗子宫肌瘤不依赖MED12突变状态
前瞻性研究纳入37例未治疗子宫肌瘤女性,比较肌瘤与肌层组织及原代细胞在维生素D处理前后的Wnt/β-catenin和TGFβ通路及增殖变化。结果显示46%肌瘤存在MED12突变,维生素D可显著降低突变型和野生型细胞的PCNA表达并抑制Wnt/β-catenin和TGFβ通路,提示其对不同分子亚型肌瘤均有效。
要点
- 46%子宫肌瘤存在MED12突变,相邻肌层未检测到突变
- 维生素D显著降低MED12突变型和野生型肌瘤细胞的PCNA表达
- 维生素D抑制Wnt/β-catenin和TGFβ通路,减少MMP9表达
核心结论
- 维生素D可抑制不同MED12突变状态子宫肌瘤原代细胞的增殖及Wnt/β-catenin和TGFβ通路。
研究设计与样本
- 前瞻性研究比较肌瘤与肌层组织及原代细胞,按MED12突变状态分析,纳入37例未治疗子宫肌瘤女性。
主要发现
- 46%的肌瘤存在MED12突变,相邻肌层无突变。
- MED12突变型肌瘤中Wnt/β-catenin和TGFβ通路基因表达较配对肌层显著升高,野生型肌瘤无显著差异。
- 维生素D显著降低突变型和野生型原代细胞的PCNA表达。
- 维生素D降低两组WNT4和β-catenin表达,其中WNT4在突变型样本中差异显著。
- 维生素D显著抑制两组TGFβ3表达,MMP9表达亦下降。
临床怎么用
- 维生素D可能作为减少不同分子亚型子宫肌瘤增殖和细胞外基质形成的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether vitamin D (VitD) inhibits cell proliferation and Wnt/β-catenin and transforming growth factor-β (TGFβ) signaling pathways in uterine leiomyomas independent of mediator complex subunit 12 (MED12) mutation status. DESIGN: Prospective study comparing leiomyoma vs. myometrial tissues and human uterine leiomyoma primary (HULP) cells treated with or without VitD and analyzed by MED12 mutation status. SETTING: Hospital and university laboratories. PATIENT(S): Women with uterine leiomyoma without any treatment (n = 37). INTERVENTION(S): Uterine leiomyoma and myometrium samples were collected from women undergoing surgery because of symptomatic leiomyoma pathology. MAIN OUTCOME MEASURE(S): Analysis of Wnt/β-catenin and TGFβ pathways and proliferation by quantitative real-time polymerase chain reaction in leiomyoma and myometrial tissue as well as in VitD-treated HULP cells analyzed by Sanger sequencing. RESULTS: Sequencing data showed that 46% of leiomyomas presented MED12 mutation, whereas no mutations were detected in adjacent myometrium. Expression of Wnt/β-catenin and TGFβ pathway genes was significantly increased in MED12-mutated leiomyomas compared to matched myometrium; no significant differences were found in wild-type (WT) leiomyomas. In HULP cells, VitD significantly decreased PCNA expression of both MED12-mutated and WT groups. VitD treatment decreased WNT4 and β-catenin expression in both groups compared to controls, with significance for WNT4 expression in MED12-mutated samples. Similarly, VitD significantly inhibited TGFβ3 expression in cells from both groups. MMP9 expression also decreased. CONCLUSION: Despite molecular differences between MED12-mutated and WT leiomyomas, VitD inhibited Wnt/β-catenin and TGFβ pathways in HULP cells, suggesting VitD as an effective treatment to reduce proliferation and extracellular matrix formation in different molecular subtypes of uterine leiomyomas.
引用
- Corachán A, Trejo MG, Carbajo-García MC, et al. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation. Fertil Steril. 2020. PMID: 33036796. doi:10.1016/j.fertnstert.2020.07.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。